ÐÂÒ»´úP-CABÑÎËá¿ÆÕÀÉúµ¥¼ÁÁ¿µÝÔö¢ñÆÚÑо¿Ð§¹ûÐû²¼£¡
2023Äê9ÔÂ15ÈÕ£¬ÓɿʱAGµÇ¼Èë¿ÚÒ½Ò©¶À¼ÒÉÌÒµ»¯µÄÊ׿î¹ú²ú×ÔÖ÷Ñз¢µÄ¼ØÀë×Ó¾ºÕùÐÔËá×èÖͼÁ£¨P-CAB£©ÑÎËá¿ÆÕÀÉúƬ£¨ÉÌÆ·Ãû£º±¶ÎÈ®£©ÔÚ¿µ½¡ÊÜÊÔÕßÖпªÕ¹µÄµ¥¼ÁÁ¿µÝÔö¢ñÆÚÑо¿Ð§¹ûÕýʽÔÚÏß½ÒÏþÓÚEuropean Journal of Pharmaceutical Sciences£¨IF=4.6£©1¡£
2023Äê2ÔÂ15ÈÕ£¬ÑÎËá¿ÆÕÀÉú»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©Åú×¼£¬ÓÃÓÚÊ®¶þÖ¸³¦À£Ññ£¨DU£©ºÍ·´Á÷ÐÔʳ¹ÜÑ×£¨RE£©µÄÖÎÁÆ£¬³ÉΪº£ÄÚΨһͬʱ»ñÅú˫˳Ӧ֢µÄP-CAB£¬ÔÚÒѽÒÏþµÄÊ®¶þÖ¸³¦À£ÑñµÄ¢ò¡¢¢óÆÚÑо¿ºÍ·´Á÷ÐÔʳ¹ÜÑ×¢óÆÚÑо¿ÖУ¬20 mg ÑÎËá¿ÆÕÀÉúÖÎÁÆÊ®¶þÖ¸³¦À£ÑñºÍ·´Á÷ÐÔʳ¹ÜÑ×µÄÁÆЧºÍÄÍÊÜÐÔ»ñµÃ֤ʵ2-4£¬Ñо¿Ð§¹ûÖ§³ÖÑÎËá¿ÆÕÀÉúÓÃÓÚÖÎÁÆÊ®¶þÖ¸³¦À£ÑñºÍ·´Á÷ÐÔʳ¹ÜÑס£±¾´Î½ÒÏþµÄÑÎËá¿ÆÕÀÉúµ¥´ÎµÝÔö¢ñÆÚÑо¿Êý¾Ý£¬Ñо¿Ñ¡È¡À¼Ë÷Àßò×÷ΪÑôÐÔ±ÈÕÕÒ©£¬Í¬Ê±½ÏÁ¿ÆÊÎöÁËÑÎËá¿ÆÕÀÉúºÍÀ¼Ë÷ÀßòµÄÒ©´ú¶¯Á¦Ñ§£¨PK£©ºÍҩЧ¶¯Á¦Ñ§£¨PK£©ÌØÕ÷¡£
Ñо¿Éè¼Æ
±¾Ñо¿ÎªËæ»ú¡¢Ë«Ã¤¡¢ÑôÐÔÒ©/ο½å¼Á±ÈÕÕÑо¿£¬Èë×éÄêËêΪ18 ~45 ÖÜË꣨º¬18 ºÍ45 ÖÜË꣩µÄ¿µ½¡³ÉÄêÊÜÊÔÕߣ¬¹²Éè5 ¸öÑÎËá¿ÆÕÀÉú¼ÁÁ¿×飨5mg¡¢10mg¡¢20mg¡¢40mg¡¢60mg£©¡£Ç°8λÊÜÊÔÕ߶¼ÄÉÈë5mg¼ÁÁ¿×é½ÓÊÜÑÎËá¿ÆÕÀÉú£¬ºóÐøÊÜÊÔÕßƾ֤ǰһ¼ÁÁ¿×éµÄÄÍÊÜÐÔÇéÐΣ¬ÒÀ´Î½øÈë10mg¡¢20mg¡¢40mg¡¢60mg¼ÁÁ¿×飬ÿ×éÈë×é12ÀýÊÜÊÔÕßÒÔ4:1:1µÄ±ÈÀýËæ»ú½ÓÊÜÑÎËá¿ÆÕÀÉú¡¢30mgÀ¼Ë÷ÀßòºÍο½å¼Á¡£Ö÷ÒªÑо¿ÖÕµãΪµ¥´Î¿Ú·þÑÎËá¿ÆÕÀÉúµÄÇå¾²ÐÔºÍÄÍÊÜÐÔ¡£´ÎÒªÑо¿ÖÕµãΪµ¥´Î¿Ú·þÑÎËá¿ÆÕÀÉúµÄÈËÌåÒ©´ú¶¯Á¦Ñ§ºÍҩЧ¶¯Á¦Ñ§ÌØÕ÷¡£
Ñо¿Ð§¹û
Ñо¿¹²Èë×é56ÀýÊÜÊÔÕߣ¬½ÓÊÜÑÎËá¿ÆÕÀÉú¡¢30 mg À¼Ë÷ÀßòºÍο½å¼ÁµÄÊÜÊÔÕßÑо¿Ê±´ú²»Á¼ÊÂÎñµÄ±¬·¢ÂÊ»®·ÖΪ32.5%£¬50.0%£¬37.5%£¬ÑÏÖØˮƽ¶¼ÎªÇáÖжȣ¬ÎÞÑÏÖز»Á¼ÊÂÎñ±¬·¢¡£µ¥´Î¿Ú·þ5mg¡¢10mg¡¢20mg¡¢40mg ºÍ60mgÑÎËá¿ÆÕÀÉúºó£¬ÆäTmaxµÄÖÐλÊýΪ1.25~1.75h£¬t1/2 ¾ùÖµ¹æģΪ6.00~7.17h£¬Cmax£¨Æ½¾ùÖµ¹æÄ££º5.83 ÖÁ 89.3 ng/mL£©ºÍAUC0-¡Þ£¨Æ½¾ùÖµ¹æÄ££º54.3 ÖÁ 785 h¡¤ng/mL£©ËæןøÒ©¼ÁÁ¿µÄÔöÌí¶øÔöÌí¡£¸øÓè30 mgÀ¼Ë÷Àßòºó£¬ÆäTmaxµÄÖÐλÊýΪ1.5h£¬t1/2¾ùֵΪ2.00h¡£ÑÎËá¿ÆÕÀÉúµÄ°ëË¥ÆÚ³¤ÓÚÀ¼Ë÷Àßò¡£
¸øÓèÑÎËá¿ÆÕÀÉúºÍÀ¼Ë÷ÀßòºóθËápHֵѸËÙÉÏÉý£¬µ¥´Î¿Ú·þÀ¼Ë÷ÀßòµÄÒÖËáЧ¹û½öά³ÖÔ¼12h£¬ËæºóÖð½¥Ï½µ£¬Ò¹¼äθËáÒÖÖÆЧ¹û²î¡£ÑÎËá¿ÆÕÀÉú¹ØÓÚθËáµÄÒÖÖÆ×÷Ó÷ºÆð¼ÁÁ¿ÒÀÀµÐÔ£¬40-60
mg ÑÎËá¿ÆÕÀÉúµÄÒÖËáЧ¹ûÇ¿ÓÚ10-20 mg¡£µ¥´Î¿Ú·þ20mg-60mgÑÎËá¿ÆÕÀÉú16¸öСʱºóθËápHÖµÈÔά³ÖÔÚ6ÒÔÉÏ£¬Í¬Ê±ÊÜÊÔÕß24СʱÄÚθËápHÖµ´óÓÚ3µÄʱ¼ä°Ù·Ö±È£¨pH >3 HTR£©£¬pH >4 HTRºÍpH >5 HTR¶¼ÓÅÓÚ30 mgÀ¼Ë÷Àßò¡£
ͼ1. ·þÓÃ5mg-60mg ÑÎËá¿ÆÕÀÉú¡¢30mg À¼Ë÷Àßò»òο½å¼Áºó£¬£¨A£©24hÄÚƽ¾ùθÄÚpH -ʱ¼äÇúÏߣ¬£¨B£©48hÄÚƽ¾ùθÄÚpH -ʱ¼äÇúÏß
±í1. ¿Ú·þÑÎËá¿ÆÕÀÉú¡¢À¼Ë÷Àßò¼°Î¿½å¼Áºó£¬24h¼°Ò¹¼äƽ¾ùθpH>3¡¢pH>4¡¢pH>5 ʱ¼ä°Ù·Ö±È»ã×ÜЧ¹û
Ñо¿½áÂÛ
¿µ½¡ÊÜÊÔÕßµ¥´Î¿Ú·þ5-60mgÑÎËá¿ÆÕÀÉúµÄÄÍÊÜÐÔÓÅÒ죬20 mg¼ÁÁ¿Ï¿ɱ¬·¢ÓÅÓÚ30mg À¼Ë÷ÀßòµÄÎȹ̡¢³¤ÆÚµÄÒÖËáЧ¹û¡£
ÉóÅúÂ룺NP-MA-20230921-CN-KEV-00003
²Î¿¼ÎÄÏ×
-
1.???? Sufeng?Zhou, et al. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Eur J Pharm Sci. 2023 Sep 2;106578. doi: 10.1016/j.ejps.2023.106578.
-
2.???? Songfeng Chen, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive esophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther. 2022 Jun;55(12):1524-1533. doi: 10.1111/apt.16959.
-
3.???? Nian-di Tan, et al. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial. J Gastroenterol Hepatol. 2022 Nov;37(11):2060-2066. doi: 10.1111/jgh.16000.
-
4.???? Nian-di Tan, et al. Efficacy and safety of keverprazan compared to lansoprazole in the treatment of duodenal ulcer: a phase III, randomised, double-blind, multicentre trial. Clin Transl Gastroenterol. 2023 May 29. doi: 10.14309/ctg.0000000000000602.